GLP-1 medications are approved for chronic, long-term use with no set stopping point. The FDA classifies these drugs as treatments for “chronic weight management,” which means they’re designed to be taken indefinitely, much like blood pressure or cholesterol medications. That said, how long you actually stay on one depends on your goals, how your body responds, and whether you can maintain access.
Why These Medications Are Meant to Be Ongoing
The FDA approved both semaglutide and tirzepatide specifically for chronic weight management, not as short-term interventions. Clinical trials that led to approval measured results at 72 weeks (about a year and a half), and participants continued taking the drugs for the full duration. There was no built-in stopping point because the medications work by replacing a signal your body either doesn’t produce enough of or doesn’t respond to strongly enough. When that signal disappears, the effect disappears too.
This is the core reality of GLP-1 treatment: the drugs suppress hunger by acting on appetite centers in the brain and slowing how quickly food leaves your stomach. Once you stop, those effects reverse. Gastric emptying speeds back up relatively quickly. The brain’s appetite-suppressing signals fade soon after. Hormonal shifts that drive hunger take longer to fully return, but they do return, and behavioral patterns tend to follow.
What Happens When You Stop
The weight regain data is striking. A meta-analysis published in The Lancet’s eClinicalMedicine found that at one year after stopping a GLP-1 medication, people regained about 60% of the weight they had lost during treatment. The regain doesn’t stop there. Beyond one year, it’s estimated to plateau at roughly 75% of the lost weight eventually coming back.
This isn’t a failure of willpower. Weight loss itself triggers biological changes that push your body to regain. Fat loss lowers leptin (the hormone that signals fullness) and raises ghrelin (the hormone that signals hunger). GLP-1 drugs counteract both of those shifts while you’re taking them. When treatment ends, those hunger-promoting signals come roaring back, and the body may even overcompensate through stress-response pathways that actively promote weight regain.
Reducing the Dose Instead of Stopping
Because stopping entirely leads to significant regain, researchers are exploring whether a lower maintenance dose could work once you’ve hit your weight loss plateau. A small study from Scripps Clinic found that most participants in a 30-person group maintained their peak weight loss even after reducing how often they took their injections, going from weekly to every two weeks, and in some cases as infrequently as every six weeks. Participants kept this reduced schedule for an average of 36 weeks.
This is a promising signal, but it’s still early. There’s currently no official protocol for stepping down to a maintenance dose. As the researchers noted, once a patient reaches their maximum weight loss, there are no established guidelines for what an appropriate reduced schedule looks like. Your prescriber would need to work with you individually on any dose changes.
Long-Term Safety Considerations
If you’re taking a GLP-1 medication indefinitely, safety over years and decades matters. The two main concerns that come up are thyroid cancer and pancreatitis.
The thyroid concern originated from animal studies showing an increase in a specific type of thyroid cancer (medullary thyroid cancer) in rodents. This led the FDA to warn against using GLP-1 drugs in anyone with a personal or family history of that cancer type or a related genetic condition called MEN2. In humans, the picture looks more reassuring. A large study of over 41,000 patients starting GLP-1 therapy found no statistically significant increase in overall thyroid cancer risk. Only 0.17% received a thyroid cancer diagnosis. There was a higher detection rate in the first 12 months, but researchers attributed this to detection bias: people starting GLP-1 drugs were significantly more likely to get thyroid ultrasounds (2.1% vs. 1.5% of patients on other medications), which naturally catches more incidental findings. After the first year, the elevated detection rate disappeared entirely.
The lean mass question is also worth understanding for long-term users. About 25% of total weight lost on GLP-1 medications comes from lean mass (muscle and other non-fat tissue) rather than fat. Semaglutide and tirzepatide at their highest doses were the most effective at reducing weight and fat but among the least effective at preserving muscle. This doesn’t change your overall body composition percentage significantly, but over years, cumulative muscle loss could matter, particularly for older adults. Resistance training while on these medications is one of the most practical things you can do to offset this effect.
Insurance and Access Limits
Even though there’s no medical time limit, your insurance plan may impose its own boundaries. Coverage for GLP-1 drugs for weight management varies widely. Many private insurers require prior authorization and periodic reviews to continue coverage, often checking that you’re still losing weight or maintaining a qualifying BMI.
Medicare historically didn’t cover GLP-1 drugs for weight loss at all. That’s beginning to change. Starting July 2026, a new Medicare GLP-1 Bridge program will provide short-term coverage through the end of 2027 for eligible beneficiaries. Qualifying requires a BMI of 35 or higher, or a BMI of 30 or higher with conditions like heart failure, uncontrolled high blood pressure, or advanced kidney disease. People with a BMI of 27 or higher can also qualify if they have pre-diabetes, a history of heart attack or stroke, or symptomatic peripheral artery disease. This program is explicitly temporary, and continued access after 2027 will depend on enrolling in a Part D plan that participates in a follow-up program called BALANCE.
For many people, the practical answer to “how long can you take a GLP-1” comes down less to biology and more to cost and coverage. At list prices of $1,000 or more per month without insurance, sustained access is the real limiting factor for long-term use.
The Bottom Line on Duration
There is no maximum duration for GLP-1 therapy. These medications are designed to be taken as long as they’re working and you can access them. Stopping leads to significant weight regain in most people, driven by biological mechanisms that don’t resolve on their own. Reduced dosing schedules may eventually offer a middle path, but that approach isn’t yet part of standard guidelines. If you’re planning to start or are already on a GLP-1 medication, the most useful framing is to think of it as an ongoing treatment rather than a temporary course.